



PRESENT AND FUTURE APPROACHES TO THE CONTROL OF DYSLIPIDAEMIAS





Information about the project is available online on www.sitecs.it/dyslipidaemias



This meeting is endorsed by the European Atherosclerosis Society

PRESENT AND FUTURE APPROACHES TO THE CONTROL OF DYSLIPIDAEMIAS

Introduction and scope of the meeting (10')

- Alberico L. Catapano

- Lale Tokgözoğlu

MODULE I: GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS AND LIFESTYLE AND NUTRACEUTICAL INTERVENTIONS

Introduction

ESC/EAS 2019 Guidelines (45')

Lipids and atherosclerosis in the COVID era (15')

Lifestyle interventions and the role of nutraceuticals (30')

A pratical approach to nutraceuticals (30')

MODULE II: LIPID LOWERING THERAPIES

Introduction

Statins (30')

Ezetimibe and combination therapy (30')

PCSK9 inhibitors (30')

Novel therapeutic approaches (30')

MODULE III: CURRENT GUIDELINES AND FUTURE CHALLENGES

CHAIR: ALBERICO L. CATAPANO AND LALE TOKGÖZOĞLU

Introduction and state of the art (30')

Current guidelines and future challenges: Round table (90')

Maciej Banach, Alberico L.Catapano, Michel Farnier, Luis Masana, Matteo Pirro, and Lale Tokgözoğlu

CHAIRS

Alberico L. Catapano Lale Tokgözoğlu

FACULTY

Alberico L. Catapano Maciej Banach Luis Masana Michel Farnier Matteo Pirro Lale Tokgözoğlu

- Alberico L. Catapano - Alberico L. Catapano

- Lale Tokgözoğlu
- Maciej Banach
- Matteo Pirro
- Alberico L. Catapano
- Lale Tokgözoğlu
- Luis Masana
- Michel Farnier
- Alberico L. Catapano
- -Alberico L. Catapano

PRESENT AND FUTURE APPROACHES TO THE CONTROL OF DYSLIPIDAEMIAS - DETAILS OF THE PROJECT

Dyslipidaemias represent one of the major cardiovascular risk factors.

Many treatments are available, but the choice should take into account the therapeutic goals according to the risk class, as suggested by the new EAS-ESC guidelines.

In addition, the new guidelines recommend lowering LDL-cholesterol even under circumstances in which pharmacological intervention is not yet necessary, through an early lifestyle intervention and integrated nutrition.

The aim of this Project is to identify and suggest, in the light of scientific evidence, which are the correct approaches, pharmacological and not, according to the different risk classes and various clinical situations.

The Project involves different training opportunities with different educational materials that will be available on the dedicated website. The following deadlines are envisaged:

- 1 December 2020 Opening of the Project website. (Subscription to the newsletter dedicated to the Project).
- 22 December 2020 Opening of the webcast (webinar) with video on-demand (scientific contents of the course in preview) and availability of the slides pdf format for the download.
- January 22, 2021 (Date to be defined*) the UEMS accredited course (3 modules of 2 hours) will be available and redeemable by the participants. The course will be available until June 22 with access limited to the first 1000 registrants. A course pre-registration will open from 22 December upon access to the course.
- in January, February, March, April, May and June there will be a monthly questions & answers virtual meeting. Participants will have to register each time; you will have the opportunity to ask your questions to our experts.

Note:

Project's scientific contents (video on demand and slides) will be available since December 22. A pre-registration form will be available for the UEMS accredited course.

The UEMS accredited course will be open from January* to June with participations limited to the first 1000 subscribers.

*The course is under accreditation, as soon as available we will communicate the exact date

SCIENTIFIC SECRETARIAT:

SITeCS - Societa Italiana di Terapia Clinica e Sperimentale v ia Balzaretti, 7- 20133 Milano tel: +39 02 49636373 - fax: +39 02 49633384 e-mail: segreteria@sitecs.it

web: www.sitecs.it

Thanks to unconditional support from

